Expression of follicle-stimulating hormone receptor by the vascular endothelium in tumor metastases by Ahsan Siraj et al.
Siraj et al. BMC Cancer 2013, 13:246
http://www.biomedcentral.com/1471-2407/13/246RESEARCH ARTICLE Open AccessExpression of follicle-stimulating hormone
receptor by the vascular endothelium in tumor
metastases
Ahsan Siraj1, Virginie Desestret2, Martine Antoine3, Gaëlle Fromont4, Michel Huerre5, Marc Sanson6,
Philippe Camparo7, Christophe Pichon1, François Planeix1, Julie Gonin3, Aurelian Radu8† and Nicolae Ghinea1*†Abstract
Background: The Follicle Stimulating Hormone receptor (FSHR) is expressed by the vascular endothelium in a wide
range of human tumors. It was not determined however if FSHR is present in metastases which are responsible for
the terminal illness.
Methods: We used immunohistochemistry based on a highly FSHR-specific monoclonal antibody to detect FSHR in
cancer metastases from 6 major tumor types (lung, breast, prostate, colon, kidney, and leiomyosarcoma ) to 6
frequent locations (bone, liver, lymph node, brain, lung, and pleura) of 209 patients.
Results: In 166 patients examined (79%), FSHR was expressed by blood vessels associated with metastatic tissue.
FSHR-positive vessels were present in the interior of the tumors and some few millimeters outside, in the normally
appearing tissue. In the interior of the metastases, the density of the FSHR-positive vessels was constant up to 7 mm,
the maximum depth available in the analyzed sections. No significant differences were noticed between the density of
FSHR-positive vessels inside vs. outside tumors for metastases from lung, breast, colon, and kidney cancers. In contrast,
for prostate cancer metastases, the density of FSHR-positive vessels was about 3-fold higher at the exterior of the
tumor compared to the interior. Among brain metastases, the density of FSHR-positive vessels was highest in lung and
kidney cancer, and lowest in prostate and colon cancer. In metastases of breast cancer to the lung pleura, the
percentage of blood vessels expressing FSHR was positively correlated with the progesterone receptor level, but not
with either HER-2 or estrogen receptors. In normal tissues corresponding to the host organs for the analyzed
metastases, obtained from patients not known to have cancer, FSHR staining was absent, with the exception of approx.
1% of the vessels in non tumoral temporal lobe epilepsy samples.
Conclusion: FSHR is expressed by the endothelium of blood vessels in the majority of metastatic tumors.
Keywords: Breast cancer, Colon cancer, Kidney cancer, Lung cancer, Prostate cancer, Endothelial cells, Leiomyosarcoma,
Follicle-stimulating hormone receptor, Metastasis, Tumor blood vesselsBackground
In healthy adult humans, the follicle-stimulating hormone
receptor (FSHR) is expressed only in the granulosa cells of
the ovary and the Sertoli cells of the testis [1,2]. A minimal
expression by the endothelial cells of gonadal blood ves-
sels has also been reported [3,4]. Recently, we have shown* Correspondence: nicolae.ghinea@curie.fr
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reproduction in any medium, provided the orthat FSHR is selectively expressed on the surface of the
blood vessels of a wide range of tumors [5] and we found
that FSHR levels in primary renal cell carcinoma tumors
correlate strongly with the response of metastatic tumors
in the same patients to Sunitinib, an antiangiogenic recep-
tor tyrosine kinase inhibitor [6]. This last observation
suggests a link between FSHR expression and angiogen-
esis in metastatic tumors. However, comprehensive data
on FSHR expression in metastases are missing. From a
clinical point of view, metastases are more relevant than
the primary tumors, because metastases are responsible. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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surgically removed in most cases. Metastases are the
cause of 90% of human cancer deaths [7].
Many of the processes that occur during metastatic
tumor growth are similar to the processes in the primary
parent tumors, as indicated by similar gene expression
profiles of cells in the primary tumors and distant me-
tastases in the same patient [8].
However, significant differences between primary tumors
and metastases have been reported regarding protein
expression, including cell surface proteins and receptors
[9-11], due for instance to disparities between the char-
acteristics of cells that metastasize and cells that remain
in the primary tumor [8].
Specific properties of the host tissue could also induce
significant differences between the metastatic and the
parent tumors. For instance, vascular endothelial cells
are known to differ markedly in various organs [12-17].
As a consequence, neoangiogenic processes and the prop-
erties of the newly formed blood vessels at distant meta-
static sites could in principle display quantitative and
qualitative differences in comparison with the parent
tumors. This is the case of primary colorectal tumors
and their hepatic metastases [18-21].
In the particular case of FSHR expression, a legitimate
question is whether it is generally expressed by the
endothelium of metastatic tumors, as it is in the primary
tumors. The fact that the FSHR is present in all eleven
organs from which primary tumors have been analyzed
by us [5] indicates that FSHR expression in a tumoral
context is a general property of the vascular endothelium
in most organs. This observation suggests that vascular
FSHR expression occurs in both primary and metastatic
tumors, independently of the host tissue.
To determine if this is the case we performed immu-
nohistochemistry experiments. A highly FSHR-specific
monoclonal antibody was used to detect FSHR in cancer
metastases from 6 major types of cancers (lung, breast,
prostate, colon, kidney, and uterine corpus leiomyosarcoma)




We analyzed metastatic tissues from 209 patients who
have been subjected to surgery for removal of the meta-
static tumors at the French hospitals: Foch Hospital,
Suresnes, Tenon Hospital, Paris, La Salpêtrière Hospital,
Paris, Curie Hospital, Paris, and CHU de Poitiers.
The specimens were fixed in 10% formalin for 48 hours
and embedded in paraffin. Large sections of 1.5-2.5 cm2
were cut from the paraffin blocks corresponding to all
types of metastasis, except for breast cancer metastasis
to pleura. In the latter case tissue microarrays wereconstructed using archived formalin-fixed paraffin em-
bedded tissue [22].
All living patients provided written consent to their
medical information being used for research purposes.
The protocol was approved by the institutional review
board or ethics committee at each study site and conducted
in accordance with the Helsinki declaration.
Antibodies
The FSHR-highly specific monoclonal antibody 323 was
produced in ascites and purified as described [3]. Goat
anti-mouse IgG antibody coupled to peroxidase was pur-
chased from Sigma-Aldrich, Saint Quentin Fallavier, France.
Rabbit monoclonal anti-HER2/neu antibody 4B5 was
from Ventana, Tucson, Arizona, USA. Monoclonal anti-
estrogen receptor antibody 6F11 and monoclonal anti-
progesterone receptor antibody 1A6 were from Novocastra
Laboratories Ltd, Newcastle, UK. Vectastain Elite ABC
peroxidase mouse IgG kit was from Vector Burlingame,
CA, USA.
Chemicals
Sodium borohydride, 3-amino-9-ethylcarbazole (AEC),
sodium azide, hydrogen peroxide 30%, goat serum, and
haematoxylin Gill solution n°3 were purchased from Sigma-
Aldrich, Saint-Quentin Fallavier, France. Diaminobenzidine
was from Dako A/S, Glostrup, Denmark. Shandon Immu-
Mount medium was obtained from Thermo-Scientific,
Asniere sur Seine, France.
Immunohistochemistry
Sections (5 μm thick) have been cut from the archived
paraffin blocks, attached to SuperFrost slides, deparaffinized
with toluene, and gradually dehydrated in ethanol. Antigen
retrieval was performed by incubating slides at 90°C for
40 min with 10 mM citrate buffer, pH 6. To block en-
dogenous peroxidase activity the sections were incubated
with 6% hydrogen peroxide (15 min at RT). Sodium boro-
hydride (10 mg/ml PBS) was used to quench the free alde-
hyde groups (15 min). Non specific binding of antibodies
was blocked by incubating the slides with 2% goat serum
in PBS (blocking buffer) for 2 hours at RT. The sections
were stained using the anti-FSHR monoclonal antibody
FSHR323 (5 μg/ml) [3,5] and subsequently incubated with
a goat anti-mouse IgG antibody coupled to horseradish
peroxidase (dilution 1:500). The FSHR expression was
visualized using AEC [5]. Estrogen receptor, progesterone
receptor, and HER-2/neu immunostainings were deter-
mined as previously described [23]. The sections were
washed in distilled water containing 0.1% sodium azide
and counterstained with haematoxylin for 10 sec. The
slides were mounted in Shandon Immu-Mount medium.
The sections were analysed using an Olympus BX43
microscope with 20× and 40× objectives and an Olympus
Table 1 Patients’ characteristics
Cancer Patients
Female Male
Number Age* Number Age*
Lung adenocarcinoma 17 53 (43-69) 29 60 (45-79)
Colon adenocarcinoma 17 65 (56-74) 17 63 (50-65)
Prostate adenocarcinoma - - 76 68 (48-98)
Kidney clear cell renal carcinoma 2 65 (56-74) 3 63 (50-65)
Breast adenocarcinoma 42 52 (32-69) - -
Uterine corpus leiomyosarcoma 6 60 (19-74) - -
Total: 209 84 - 125 -
* Median (range).
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of FSHR expression was evaluated by six investigators
independently (VD, MS, MH, PC, MA, and NG). FSHR-
positive vessels were counted using a 20× objective. The
density of the FSHR-stained vessels was determined in-
dependently by four investigators (AS, AR, CP, and NG)
by counting the vessels in fields located inside the
tumor, and separately outside the tumor, at a distance of
0-3 mm from the border between the tumor and the
normally appearing tissue.Controls
Control brain samples consisted of non-tumoral tissue
temporal epilepsy (10 patients), tonsillar resection for
Chiari malformation (7), lung (3), and pleura (3), all from
patients not known to have cancer. Sections from non-
tumoral tissue of liver (5 cases), bone (2 cases), and lymphTable 2 FSHR expression in blood vessels associated with can












Uterine corpus leiomyo-sarcoma Lung 6
ND, not determined.nodes (6 cases) that routinely accompanied surgical tumor
samples were used also as negative controls.Results and discussion
FSHR expression in metastases
We investigated FSHR presence in cancer metastases
from 6 major types of cancer (lung, breast, prostate, colon,
kidney, and leiomyosarcoma) to 6 frequent locations (liver,
lymph node, bone, pleura, lung, and brain) of 209 patients
(Tables 1 and 2). All tumor types are of epithelial origin,
except for uterine corpus leiomyosarcoma which is of
mesenchymal origin. Representative images of blood ves-
sels positive for FSHR are shown in Figures 1, 2 and 3.
Overall 79.4% (n = 166) of the metastases contained
FSHR-positive vessels. No significant differences in the
staining intensity were noticed among the cancer types







Inside the tumor Outside the tumor
1 (33%) 2 (67%) 38.8 ± 13.5 117.8 ± 4.5
9 (27%) 24 (63%) 30.3 ± 17.1 74.7 ± 2.8
26 (65%) 14 (35%) 33.0 ± 14.4 90.3 ± 6.5
0 12 (100%) 98.4 ± 12.6 104.4 ± 4.9
0 27 (100%) 68.7 ± 10.4 ND
0 3 (100%) 100.5 ± 14.4 95.2 ± 7.9
1 (20%) 4 (80%) 132.7 ± 11.6 108.4 ± 9.9
1 (9%) 10 (91%) 87.6 ± 20.1 91.1 ± 5.8
1 (4%) 22 (96%) 107.6 ± 20.4 112.0 ± 12.0
4 (9%) 42 (91%) 115.1 ± 17.8 131.1 ± 7.1
0 6 (100%) 56.5 +/- 9.7 97.9 ± 10.9
Figure 1 Expression of FSHR by microvascular endothelial cells in brain metastases of four major cancers. (A,B) lung cancer; (C,D) breast
cancer; (E,F) kidney cancer; (G,H) prostate cancer. Immunohistochemical analysis was performed on paraffin-embedded sections of human
metastatic tissues using the anti-FSHR monoclonal antibody 323, followed by a secondary goat anti-mouse Ig antibody coupled to peroxidase,
visualized by the red-brown peroxidase-reaction product. Sections were also stained with hematoxylin. Arrows point to the blood vessels. The
scale bar represents 20 μm in all panels.
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the primary antibody was omitted (not shown).
FSHR expression in metastases compared with the parent
primary tumors
The density of FSHR-positive vessels was determined in
5 primary breast tumors and in 5 metastases to pleura
from the corresponding patients. The interior of the me-
tastases had on average 60% (+/-30% (SEM)) more
FSHR-positive vessels than primary tumors (p = 0.16,
t-test, paired, 2-tails). For the two cases of metastasesfor which adjacent normal tissue was available, the ex-
terior of the metastases had on average 20% more ves-
sels than the exterior of the primary tumors.
Metastases contain FSHR-positive vessels both inside and
outside the tumors
The general characteristic of the FSHR-positive vessels
in cancers is that they are located at the periphery of the
tumors, in shells that have a thickness of approximately
10 mm (range, 7 to 15) and extend a few millimeters
both inside and outside the tumor in the apparently normal
Figure 2 FSHR-expression in metastases to liver of breast cancer (A) and colon cancer (B). Immunohistochemical analysis was performed
as for the Figure 1. Arrows point to the blood vessels. bc, breast cancer; cc, colon cancer. Panels C and D show FSHR expression in the normal
appearing tissue surrounding metastasis of colon cancer to liver. Endothelial cells of the arterioles and capillaries (arrowheads) derived from the
hepatic artery (HA) express FSHR (C). The majority of the branches of the portal vein (PV) do not express FSHR. No staining is visible in the central
vein (CV) and its associated sinusoids (*) (D). The scale bar represents 20 μm in all panels.
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deeper areas of the tumors [5]. For metastases, FSHR-
positive vessels were present some few millimeters
outside the tumors, as for the primary cancers. In the
interior of the metastases, there was no decrease in the
density of the FSHR-positive vessels in the deeper areas,
up to 7 mm, the maximum depth available in the ana-
lyzed sections (Figure 1 and Table 2). For this reason, all
TMA samples of breast cancer to pleura are equally
representative, independently of their location (in the
periphery or in the interior of the tumor). No signifi-
cant differences were noticed between the density of
FSHR-positive vessels inside vs. outside tumors for me-
tastases from leiomyosarcoma and lung, breast, colon,
and kidney cancers. In contrast, for prostate cancer
metastases, the density of FSHR-positive vessels was
2.5 to 3-fold higher at the exterior of the tumor com-
pared to the interior, for all three locations (lymph
node, bone, and brain) (Table 2; p = 0.001, t-test two
tails). In a different set of cancer patients previously
analyzed [5], in non-metastatic prostate tumors there
was no significant difference between the exterior vs.
the interior of the tumor.
FSHR expression as function of the metastatic site
For some types of cancers, differences in the density of
FSHR-positive vessels occur depending on the metastasis
site. Thus, metastases of prostate cancer to brain had a
higher density of FSHR-positive vessels than metastasesto lymph nodes (Figure 4A and Table 2, p = 0.003). No
significant differences in the density of FSHR-positive
vessels were observed for breast cancer metastases to
brain vs. liver (Table 2).
Comparisons of brain metastases from various cancers
revealed that the highest density of FSHR-positive ves-
sels occurred for lung and kidney cancer, and the lowest
density for prostate and colon cancer (Figure 4B and
Table 2).
We investigated previously the vascular FSHR expres-
sion in primary tumors of metastatic renal carcinoma pa-
tients [6]. After primary tumor removal by surgery, the
response of the metastatic lesions to the antiangiogenic
drug sunitinib was highly correlated with the level of
FSHR presence in the primary tumors. This observation
supports a good correlation between the FSHR expression
in the primary and the metastatic tumors.
In liver metastases of all types of cancers, the endothe-
lial cells of the arterioles and capillaries derived from
the hepatic artery express FSHR in the adjacent tissue
located at a distance lower than approx. 1 cm from the
tumor (Figure 2C). Approximately 20% of the branches
of the portal vein in the normal tissue express FSHR
within a distance of some few millimeters from the
tumor. No staining was visible in the central veins
and its associated venules and sinusoids (Figure 2D).
FSHR presence near the bile ducts in the capillaries
and branches of the hepatic artery in the tissues adjacent
to liver metastases could be related to the observation
Figure 3 FSHR-expression in metastases of breast cancer to pleura, and of prostate cancer to lymph node and bone. Immunohistochemistry
was performed as for the preceding figures. Arrows point to blood vessels. Panel A shows specimens obtained from patients with breast cancer
localized to pleura. Panels C and E show prostate cancer that metastased to lymph node (C) and to bone (E). No staining for FSHR is observed in
blood vessels of normal tissues in pleura (B), lymph node (D), and bone (F). The scale bar represents 20 μm in all panels.
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times invade the Glisson's triad and grow along the biliary
ducts [24,25].
Correlation of FSHR expression with clinicopathological data
We used the tissue microarrays [22] to analyze by immu-
nohistochemistry the expression of multiple biomarkers
in metastases of breast cancer to the lung pleura of 27
patients. We compared the endothelial FSHR expression
with the receptor status of three most important markers
for breast cancer diagnosis and therapy (estrogen receptor,
progesterone receptor, and HER-2/neu). The percent-
age of blood vessels positive for FSHR was positively
correlated with the progesterone receptor level (r = 0.41;
n = 25; p = 0.03), but not with the other two receptors.
The density of blood vessels did not show a significant
correlation with the levels of any of the three receptors.
For the same set of samples, a correlation was detected
for the age of the patients with the microvascular density
in the tumors, and with the density of FSHR-positive
vessels (r = 0.70; n = 17; p = 0.001 in both cases). Anincrease in the vascular density in elderly patients was
recently confirmed for renal cell carcinomas [26].
FSHR in non tumoral tissue
As controls, we analyzed normal, non tumoral tissues of
pleura, lung, liver, bone, lymph nodes, and brain samples
of tonsillar resection for Chiari malformation and of
cortectomy for temporal epilepsy. The samples revealed
absence of FSHR staining (Figure 3B, D, and F), with the
exception of a low fraction of vessels stained in the epi-
lepsy samples (on average approx. 1% of the vessels,
range 0 - 4.6%).
FSHR as a tumor endothelial cell marker
Several markers have been described to be preferentially
expressed on blood vessels in tumors (e.g., prostate spe-
cific membrane antigen, αvβ3-integrin, vascular endothe-
lial growth factor and its receptors, endoglin, etc.) and in
the extracellular matrix surrounding newly formed blood
vessels (Tenascin-C, matrix metalloproteinases, Robo-4)
[27]. Current approaches, which are quite promising in
Figure 4 Density of FSHR-positive vessels in metastases. A) Metastases of prostate cancer to brain, lymph nodes, and bone. B) Metastases to
brain of tumors from prostate, breast, kidney, colon, and lung. White and black bars represent vessel densities inside and outside tumors,
respectively. Error bars: standard error of the mean.
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liver therapeutics to the tumour vasculature. This was
first shown by Hood and his collaborators [28] who
used integrin αvβ3-targeted nanoparticles to selectively
deliver a mutant Raf1 gene to the tumour vasculature,
resulting in apoptosis of endothelial cells and tumour
regression.
Integrins do not allow, however, very specific targeting of
tumors, and we expect that targeting FSHR will be much
more effective. Immunoelectron microscopy experiments
with mice that carried LNCaP human xenograft tumors in-
dicate that the FSHR is expressed on the luminal surface of
the endothelial cells lining the tumor vessels, in direct con-
tact with the blood [5]. Thus tumor imaging agents, based
on FSH or the anti-FSHR-ectodomain antibodies that
bind with high affinity to the endothelial FSHR, could
be injected in the vasculature and would make visibleprimary and metastatic tumors located anywhere in the
body using magnetic resonance imaging, positron emis-
sion tomography, or ultrasound imaging [29]. Our re-
sults suggest that FSHR will be able to act as a general
target for anti-cancer drugs as well as for agents which
destroy or block blood vessels in tumours. Because
FSHR is notably absent in most healthy tissues, its use
could help minimize the damage that anti-cancer drugs
do to surrounding tissue or organs.Conclusions
Our data show that FSHR is expressed by the microvascu-
lature of metastatic tumors. This fact strongly increases
FSHR potential relevance as a clinical target for cancer im-
aging and for therapy, especially for tumors that are highly
resistant to currently available antiangiogenic treatments.
Siraj et al. BMC Cancer 2013, 13:246 Page 8 of 8
http://www.biomedcentral.com/1471-2407/13/246Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
NG, AR conceived and designed the experiments. AS, CP, FP performed the
experiments. VD, MA, GF, MS, MH, PC, MS, JG performed histologic analysis.
AS, CP, AR, NG analyzed the data. AR, NG wrote the paper. All authors read
and approved the final manuscript.
Acknowledgements
This work was supported by INSERM. We thank Anita Rodenas, Karima
Mouslim, Eliane Padoy, André Nicolas, and Julie Godet for excellent technical
assistance.
Author details
1Inserm Equipe Angiogenèse Tumorale, Institut Curie, Centre de Recherche,
Département Recherche Translationnelle, 26 rue d’Ulm, 75005, Paris, France.
2AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratoire de Neuropathologie,
R. Escourolle, Paris, France. 3Département de Pathologie, Hôpital Tenon, Paris,
France. 4Département de Pathologie, CHU de Poitiers, 86000, Poitiers, France.
5Département de Pathologie, Paris, France; Institut Pasteur, Department
Infection et Epidémiologie, Hôpital Curie, Paris, France. 6Inserm-UMR975; AP-
HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2, Paris,
France. 7Centre de Pathologie Amiens, Amiens, France. 8Icahn School of
Medicine at Mount Sinai, New York, NY, USA.
Received: 17 December 2012 Accepted: 16 May 2013
Published: 20 May 2013
References
1. Sprengel R, Braun T, Nikolics K, Segaloff DL, Seeburg PH: The testicular
receptor for follicle-stimulating hormone: structure and functional
expression of cloned cDNA. Mol Endocrinol 1990, 4:525–530.
2. Simoni M, Gromoll J, Nieschlag E: The follicle stimulating hormone
receptor: biochemistry, molecular biology, physiology, and
pathophysiology. Endocr Rev 1997, 18:739–773.
3. Vannier B, Loosfelt H, Meduri G, Pichon C, Milgrom E: Anti-human FSH
receptor monoclonal antibodies: immunochemical and
immunocytochemical characterization of the receptor. Biochemistry 1996,
35:1358–1366.
4. Vu Hai MT, Lescop P, Loosfelt H, Ghinea N: Receptor-mediated transcytosis
of follicle stimulating hormone through the rat testicular
microvasculature. Biol Cell 2004, 96:133–144.
5. Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A, Fromont G,
Vu Hai MT, Ghinea N: Expression of follicle-stimulating hormone receptor
in tumor blood vessels. N Engl J Med 2010, 363:1621–1630.
6. Siraj MA, Pichon C, Radu A, Ghinea N: Endothelial FSH receptor in primary
kidney cancer correlates with subsequent response to sunitinib. J Cell
Mol Med 2012, 16:2010–2016.
7. Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, van't Veer LJ:
Gene expression profiles of primary breast tumors maintained in distant
metastases. Proc Natl Acad Sci USA 2003, 100:15901–15905.
8. Weigelt B, Peterse JL, van’t Veer LJ: Breast cancer metastasis: markers and
models. Nature Rev Cancer 2005, 5:591–602.
9. Takes RP, Baatenburg de Jong RJ, Wijffels K, Schuuring E, Litvinov SV,
Hermans J, van Krieken JH: Expression of genetic markers in lymph node
metastases compared with their primary tumours in head and neck
cancer. J Pathol 2001, 194:298–302.
10. Ljuslinder I, Malmer B, Isaksson-Mettävainio M, Oberg A, Henriksson R,
Stenling R, Palmqvist R: ErbB 1-4 expression alterations in primary
colorectal cancers and their corresponding metastases. Anticancer Res
2009, 29:1489–1494.
11. Stoecklein NH, Klein CA: Genetic disparity between primary tumours,
disseminated tumour cells, and manifest metastasis. Int J Cancer 2010,
126:589–598.
12. Aird WC: Phenotypic heterogeneity of the endothelium: I. Structure,
function, and mechanisms. Circ Res 2007, 100:158–173.
13. Aird WC: Phenotypic heterogeneity of the endothelium: II.
Representative vascular beds. Circ Res 2007, 100:174–190.
14. Boegehold MA: Heterogeneity of endothelial function within the
circulation. Curr Opin Nephrol Hypertens 1998, 7:71–78.15. Ribatti D, Nico B, Vacca A, Roncali L, Dammacco F: Endothelial cell
heterogeneity and organ specificity. J Hematother Stem Cell Res 2002,
11:81–90.
16. Thorin E, Shreeve SM: Heterogeneity of vascular endothelial cells in
normal and disease states. Pharmacol Ther 1998, 78:155–166.
17. Ghinea N, Milgrom E: Transport of protein hormones through the
vascular endothelium. J Endocrinol 1995, 145:1–9.
18. Nakamoto RH, Uetake H, Iida S, Kolev YV, Soumaoro LT, Takagi Y, Yasuno M,
Sugihara K: Correlations between cyclooxygenase-2 expression and
angiogenic factors in primary tumors and liver metastases in colorectal
cancer. Jpn J Clin Oncol 2007, 37:679–685.
19. Rajaganeshan R, Prasad R, Guillou PJ, Chalmers CR, Scott N, Sarkar R, Poston G,
Jayne DG: The influence of invasive growth pattern and microvessel density
on prognosis in colorectal cancer and colorectal liver metastases. Br J
Cancer 2007, 96:1112–1117.
20. Mooteri S, Rubin D, Leurgans S, Jakate S, Drab E, Saclarides T: Tumor
angiogenesis in primary and metastatic colorectal cancers. Dis Colon
Rectum 1996, 39:1073–1080.
21. Prall F, Gringmuth U, Nizze H, Barten M: Microvessel densities and
microvascular architecture in colorectal carcinomas and their liver
metastases: significant correlation of high microvessel densities with
better survival. Histopathology 2003, 42:482–491.
22. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S,
Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for
highthroughput molecular profiling of tumor specimens. Nat Med 1998,
4:844–847.
23. Reyal F, Rouzier R, Depont-Hazelzet B, Bollet MA, Pierga JY, Alran S, Salmon RJ,
Fourchotte V, Vincent-Salomon A, Sastre-Garau X, Antoine M, Uzan S,
Sigal-Zafrani B, De Rycke Y: The molecular subtype classification is a
determinant of sentinel node positivity in early breast carcinoma.
PLoS One 2011, 6(5):e20297. doi:10.1371/journal.pone.0020297.
24. Tokai H, Kawashita Y, Eguchi S, Kamohara Y, Takatsuki M, Okudaira S, Tajima Y,
Hayashi T, Kanematsu T: A case of mucin producing liver metastases with
intrabiliary extension. World J Gastroenterol 2006, 12:4918–4921.
25. Uehara K, Hasegawa H, Ogiso S, Sakomoto E, Igami S, Mori T: Intrabiliary
polypoid growth of liver metastasis from colonic adenocarcinoma with
minimal invasion of the liver parenchyma. J Gastroenterol 2004, 39:72–75.
26. Meehan B, Appu S, St Croix B, Rak-Poznanska K, Klotz L, Rak J: Age-related
properties of the tumour vasculature in renal cell carcinoma. BJU Int
2011, 107:416–424.
27. Stollman TH, Ruers TJ, Oyen WJ, Boerman OC: New targeted probes for
radioimaging of angiogenesis. Methods 2009, 48:188–192.
28. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA:
Tumor regression by targeted gene delivery to the neovasculature.
Science 2002, 296:2404–2407.
29. Ghinea N: A novel role for FSH receptor as a tumor endothelial cell
marker. Acta Endocrinologica (Buc) 2010, 6:507–512.
doi:10.1186/1471-2407-13-246
Cite this article as: Siraj et al.: Expression of follicle-stimulating hormone
receptor by the vascular endothelium in tumor metastases. BMC Cancer
2013 13:246.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
